ACCEPTANCE REVIEW MEMO (ARM)

Licensee: Bonner General Hospital **License No.:** 11-27785-01

Docket No.: 030-36658 **Mail Control No.:** 471057

Type of Action: Notify **Date of Requested Action:** 08-02-06

Reviewer Assigned: **ARM reviewer(s):** Torres

Response	Deficiencies Noted During Acceptance Review
RTC	[ ] Open ended possession limits. Limit possession. Submit inventory. [ ] Submit copies of most recent leak test results. [ ] Add - delete IC license condition. Add IC paragraph in cover letter. [ ] Split license from cover letter. Add SUNSI marking to license. [ ] Ask the licensee if they have any type-amount of EPAct Material.

Reviewer's Initials: _____ **Date:** _____

☐Yes ☐No	Unrestricted release Group 2 or >: Transfer memo to FCDB within 10 days.
☐Yes ☐No	Decommissioning notification should be completed within 30 days.
☐Yes ☐No	Termination request < 90 days from date of expiration
☐Yes ☐No	Expedite (medical emergency, no RSO, location of use/storage not on license, RAM in possession not on license, other)
☐Yes ☐No	TAR needed to complete action.

Branch Chief's and/or Sr. HP's Initials: _____ **Date:** _____

SUNSI Screening according to RIS 2005-31

☐Yes ☑No **Non-Publicly Available, Sensitive** if any item below is checked

General guidance:

_____RAM = or > than Category 3 (Table 1, RIS 2005-31), use Unity Rule
_____Exact location of RAM (whether = or > than Category 3 or not)
_____Design of structure and/or equipment (site specific)
_____Information on nearby facilities
_____Detailed design drawings and/or performance information
_____Emergency planning and/or fire protection systems

Specific guidance for medical, industrial and academic (above Category 3):

_____RAM quantities and inventory
_____Manufacturer's name and model number of sealed sources & devices
_____Site drawings with exact location of RAM, description of facility
_____RAM security program information (locks, alarms, etc.)
_____Emergency Plan specifics (routes to/from RAM, response to security events)
_____Vulnerability/security assessment/accident-safety analysis/risk assess
_____Mailing lists related to security response

Branch Chief's and/or Sr. HP's Initials: RTC **Date:** 8/4/06

Pre-Licensing Screening

Applicant Information: **Control No.** 471057

Name: Bonner General Hospital	Type of Request: Amend Program Code(s):
Location: ID	License No.: 11-27785-01 Docket No.: 030-36658

STEP 1–Radioactive Materials and Quantities Requested:

		Yes or No
Instructions for Step 1: **Complete Step 1 for all applications**. If all your responses in Step 1 are "No" then do not complete Step 2 (Screening Criteria). Sign and date the completed step-sheet and add it as the sensitive and non-publicly available OAR in ADAMS. If a "yes" response is indicated for any item in Step 1, also complete Step 2. If the type of use is subject to a Security Order or the requirements for increased controls, complete Step 3 (Item A or Item B) without delay.		
A.	The request is from a new applicant.	NO
B.	NUREG-1556, Volume 20, Section 4.9 indicates a licensing site visit is needed for the requested type of use, e.g., (1) Type A broad scope license, (2) panoramic irradiator containing > 10000 curies, (3) manufacturers or distributors using unsealed radioactive material or significant quantities of sealed material, (4) radioactive waste brokers, (5) radioactive waste incinerators, (6) commercial nuclear laundries, and (7) any other application that in the judgement of the reviewer and cognizant supervisor involves complex technical issues, complex safety questions, or unprecedented issues that warrant a site visit.	NO
C.	The applicant requested certain radionuclides and quantities that equal or exceed the Risk Significant Quantity (TBq) values in the table, below, that have been "highlighted" by the reviewer	NO

Table of Risk Significant Quantities

(Category 2 Quantities, IAEA Safety Guide No. RS-G-1.9, Categorization of Radioactive Sources, August 2005)

Radionuclide	Risk Significant Quantity (TBq[1])	Risk Significant Quantity (Ci[1])	Radionuclide	Risk Significant Quantity (TBq[1])	Risk Significant Quantity (Ci[1])
Am-241	0.6	16	Pm-147	400	11,000
Am-241/Be	0.6	16	Pu-238	0.6	16
Cf-252	0.2	5.4	Pu-239/Be	0.6	16
Cm-244	0.5	14	Ra-226[2]	0.4	11
Co-60	0.3	8.1	Se-75	2	54
Cs-137	1	27	Sr-90 (Y-90)	10	270
Gd-153	10	270	Tm-170	200	5,400
Ir-192	0.8	22	Yb-169	3	81

[1] The primary values are TBq. The curie (Ci) values are for informational purposes only.

[2] The Atomic Energy Act, as amended by the Energy Policy Act of 2005, authorizes NRC to regulate Ra-226 and NRC is in the process of amending its regulations for discrete sources of Ra-226.

	Yes , No, or Not Applicable (NA)
Calculations of the Total Activity or the Unity Rule are attached to document whether or not the screening criteria in Step 2 were also completed to evaluate the application. **NOTE–If an amendment of an existing license is being requested, the calculations *will include the previously authorized quantities for the radionuclide(s).***	
Total Activity–multiple activities are requested for a single radionuclide and the sum of the activities equals or exceeds the quantity of concern for the radionuclide	—
Unity Rule--multiple radionuclides are requested and the sum of the ratios equals or exceeds unity, e.g.,[(total activity for radionuclide A) ÷ (risk significant quantity for radionuclide A)] + [(total activity for radionuclide B) ÷ (risk significant quantity for radionuclide B)] ≥ 1.0.	—

Signature and Date for Step 1:

RTC 8/4/06

License Reviewer and Date

BGH BONNER GENERAL HOSPITAL, INC.

RECEIVED
JUL 26 2006
DNMS

July 21, 2006

Licensing Division
US Nuclear Regulatory Commission
Region IV
611 Ryan Plaza Drive, Suite 400
Arlington, TX 76011-4005

Subj: Notification for License Number 11-27785-01, Docket Number 030-36658

Dear Madam or Sir:

Pursuant to 10 CFR 35.14 (a), this letter serves as a notification to your office that we wish to add Charles William Maille, M.D. to our radioactive materials license as a physician authorized user for radioactive materials use under 10 CFR 35.100 and 200. In accordance with the above regulation, as well as 10 CFR 35.59, a copy of the NRC license naming Dr. Maille as an authorized user is enclosed with this letter.

Please contact Dr. Weber, our Radiation Safety Officer, at (208) 263-1143, extension 1602 if you have any questions concerning this amendment request.

Sincerely,

Sheryl Rickard

Sheryl Rickard
Chief Executive Officer

Enclosure

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 5 PAGES

Amendment No. 47

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated **August 30, 2005,**
1. North Memorial Medical Center Department of Radiology	3. License number 22-05792-01 is amended in its entirety to read as follows:
2. 3300 Oakdale North Robbinsdale, MN 55422	4. Expiration date January 31, 2011 5. Docket No. 030-02228 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200 (excluding xenon-133)	B. Any (excluding generators)	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. As needed (not to exceed one curie of iodine-131)
D. Any byproduct material permitted by 10 CFR 35.400	D. Any brachytherapy source permitted by 10 CFR 35.400	D. 700 millicuries
E. Any byproduct material identified in 10 CFR 31.11	E. Prepackaged kit	E. As needed
F. Cesium-137	F. Sealed source (3M Model 6D6C)	F. 150 millicuries

9. Authorized Use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300 (limited to out patient procedures only).

D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION	PAGE 2 of 5 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET		License Number 22-05792-01
		Docket or Reference Number 030-02228
		Amendment No. 47

E. **In vitro** studies.

F. For storage only incident to disposal.

CONDITIONS

10. A. Licensed material may be used or stored only at the licensee's facilities located at 3300 Oakdale North, Robbinsdale, Minnesota and at **North Memorial Outpatient Care Center, 3435 West Broadway, Robbinsdale, Minnesota.**

B. Licensed material in Subitem Nos. 6.S. may be used and stored at the licensee's facilities located at 3300 Oakdale North, Robbinsdale, Minnesota.

11. A. The Radiation Safety Officer for this license is Mary Fox, M.S.

B. Authorized Medical Physicists: Mary Fox, M.S., Loretta Kwandowski, Ph.D., and Nagarajan Kadhan.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as authorized users or authorized medical physicist in accordance with 10 CFR 35.[illegible] and [illegible].

B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Kenneth B. Cram, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133), 35.300 (limited to out patient procedures only) and 31.11.
Eduard Michel, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133), 35.300 (limited to iodine-131 out patient procedures only) and 31.11.
Richard W. Carlson, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133), 35.300 (limited to out patient procedures only) and 31.11.
Robert Haselow, M.D.	10 CFR 35.300 (limited to out patient procedures only) and 35.400 .
Charles William Maile, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133), 35.300 (limited to out patient procedures only) and 31.11.
Douglas John Olson, M.D.	10 CFR 35.400.
Brian Thomas Larkin, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) and 31.11.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
22-05792-01

Docket or Reference Number
030-02228

Amendment No. 47

Richard F. Diaz, M.D.	10 CFR 35.400.
William N. Lisberg, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) and 35.300 (limited to out patient procedures only).
Thomas Peltola, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) 35.300 (limited to iodine-131 out patient procedures only) and 31.11.
Robert A. Pollock, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133). 35.300 (limited to out patient procedures only) and 31.11.
Kurt Nisi, M.D.	10 CFR 35.300 (limited to out patient procedures only), 35.400.
Richard D. Belkin, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) 35.300 (limited to iodine-131 out patient procedures only) and 31.11.
Scott Schultz, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133), 35.300 (limited to out patient procedures only) and 31.11.
Mary D. McLaurin, M.D.	10 CFR 35.200 (excluding generators and xenon-133) limited to cardiovascular clinical procedures.
Jeffery Groffsky, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) and 31.11.
Nellie Bauer, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) 35.300 (limited to iodine-131 out patient procedures only) and 31.11.
Brian DeMichaelis, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) 35.300 (limited to iodine-131 out patient procedures only) and 31.11.
Patricia E. Bruer, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133), 35.300 (limited to iodine-131 out patient procedures only) and 31.11.
Keith J. Edinburgh, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) 35.300 (limited to iodine-131out patient procedures only) and 31.11.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION	PAGE 4 of 5 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET		License Number 22-05792-01
		Docket or Reference Number 030-02228
		Amendment No. 47

Timothy J. Reiners, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) 35.300 (limited to iodine-131 out patient procedures only) and 31.11.
Dennis A. Woolner, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) 35.300 (limited to iodine-131 out patient procedures only) and 31.11.
Dominic A. Plucinski, M.D.	10 CFR 35.100, 35.200 (excluding generators, gasses, and aerosols) limited to cardiovascular clinical procedures only.
David P. Wicklund, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) and 31.11.
Maria Gomes, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) 35.300 (limited to iodine-131 out patient procedures only) and 31.11.
Mark Pilot, M.D.	10 CFR 35.100, 35.200 (excluding generators and xenon-133) 35.300 (limited to iodine-131 out patient procedures only) and

13. The licensee shall follow Regulatory Guide 8.39 "Release of Patients Administered Radioactive Materials" for the release of patients receiving brachytherapy or radiopharmaceutical therapy.

14. A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed 6 months or at such other intervals as specified by the certificate of registration referred to in 10 CFR 32.210.

    B. In the absence of a certificate from a transferor indicating that a leak test has been made within 6 months prior to the transfer, a sealed source or detector cell received from another person shall not be put into use until tested.

    C. Sealed sources need not be leak tested if:

        (i) they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha emitting material; or

        (ii) they are not designed to emit alpha particles, are in storage, and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source or detector cell shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION	PAGE 5 of 5 PAGES
MATERIALS LICENSE **SUPPLEMENTARY SHEET**	License Number 22-05792-01	
	Docket or Reference Number 030-02228	
	Amendment No. 47	

D. **The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.**

E. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically licensed by the Commission or an Agreement State to perform such services.

15. The licensee shall conduct a physical inventory every 6 months to account for all sealed sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 5 years from the date of each inventory, and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.

16. In addition to the possession limits in Item 8, the licensee shall not further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

17. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

18. **Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.**

A. Application dated November 28, 2000; and,

B. Letters dated February 23, 2001, June 6, 2001, June 27, 2001, July 29, 2002, November 8, 2004; April 4, 2005; and

C. Letter received December 21, 2001.

For the U.S. Nuclear Regulatory Commission

Date SEP 14 2005

By _____
William P. Reichhold
Materials Licensing Branch
Region III

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

(FOR LFMS USE)
INFORMATION FROM LTS

Program Code: 02121
Status Code: 0
Fee Category: 7C
Exp. Date: 20141031
Fee Comments: _____
Decom Fin Assur Reqd: N

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED
   Applicant/Licensee: BONNER GENERAL HOSPITAL
   Received Date: 20060726
   Docket No: 3036658
   Control No.: 471057
   License No.: 11-27785-01
   Action Type: Amendment

2. FEE ATTACHED
   Amount: _____
   Check No.: _____

3. COMMENTS

Signed Colleen Murnahan
Date 8-02-06

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered /__/)

1. Fee Category and Amount: _____

2. Correct Fee Paid. Application may be processed for:
   Amendment _____
   Renewal _____
   License _____

3. OTHER _____
   _____

Signed _____
Date _____

.52

FedEx Express **US Airbill**

FedEx Tracking Number 8559 5020 5667

RECIPIENT: PEEL HERE

fedex.com 1.800.GoFedEx 1.800.463.3339

1 From This portion can be removed for Recipient's records

Date FedEx Tracking Number 855950205667

Sender's Name Phone

Company

Address Dept./Floor/Suite/Room

City State ZIP

RECEIVED JUL 26 2006 DNMS

2 Your Internal Billing Reference

3 To

Recipient's Name Phone

Company

Recipient's Address Dept./Floor/Suite/Room

We cannot deliver to P.O. boxes or P.O. ZIP codes.

Address

To request a package be held at a specific FedEx location, print FedEx address here.

City State ZIP

8559 5020 5667

4a Express Package Service *Packages up to 150 lbs.*

- FedEx Priority Overnight — Next business morning.* Friday shipments will be delivered on Monday unless SATURDAY Delivery is selected.
- FedEx Standard Overnight
- FedEx First Overnight
- FedEx 2Day — Second business day.* Thursday shipments will be delivered on Monday unless SATURDAY Delivery is selected.

FedEx Envelope rate not available. Minimum charg

4b Express Freight Service

- FedEx 1Day Freight* — Next business day.** Friday shipments will be delivered on Monday, unless SATURDAY Delivery is selected

* Call for Confirmation:

5 Packaging

- FedEx Envelope*
- FedEx Pak* — Includes FedEx Sm, FedEx Large Pak, a

6 Special Handling

- SATURDAY Delivery — Not available for FedEx Standard Overnight, FedEx First Overnight, FedEx Express Saver, or FedEx 3Day Freight

Does this shipment contain dangerous go

One box must be checked.

- No
- Yes — As per attached Shipper's Declaration.
- Yes — Shippe not re

Dangerous goods (including dry ice) cannot be shipped in Fedl

7 Payment *Bill to:* Enter FedEx A

- Sender — Acct. No. in Section 1 will be billed.
- Recipient

Total Packages Total Weig

†Our liability is limited to $100 unless you declare a higher va

8 *NEW* Residential Delivery S

- No Signature Required — Package may be left without obtaining a signature for delivery
- Direct Signature — Anyone at recipient's address may sign for delivery. *Fee applies.*
- Indirect Signature — If no one is available at recipient's address, anyone at a neighboring address may sign for delivery. *Fee applies.*

519

Rev. Date 8/05•Part #156279•©1994-2005 FedEx•PRINTED IN U.S.A.•SRF

FedEx emp: 224715 25JUL06

TRK# 8559 5020 5667

76011 -TX-US

FORM 0215 JUL 26 2006 DFW

SE FWHA

27JUL06 A1

Deliver By:

** 2DAY **

THU